ReviewInternational journal of molecular sciences2021
Diabetes and Cognitive Impairment: A Role for Glucotoxicity and Dopaminergic Dysfunction.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 2 syntheses or guidelines pooled it, 112 citations in OpenAlex.
- Mechanisms and Pathogenesis of Diabetic Cognitive Impairment: A Comprehensive Review.Aging and disease · 2025Pooled it
- Prevalence and determinants of cognitive impairment in older adults with stroke in China: a systematic review.Frontiers in public health · 2025Pooled it
- Prefrontal oxygenation and working memory in patients with type 2 diabetes mellitus following integrated yoga: a randomized controlled trial.Acta diabetologica · 2023Trial
- Glucose-Lowering Therapies and Cognitive Decline: From Molecular Mechanisms to Clinical Evidence and Future Perspectives.Advances in therapy · 2026Review
- Polyethylene glycol loxenatide improves cognitive and emotional performance in patients with type 2 diabetes: a 12-week multicenter clinical observational study.Journal of endocrinological investigation · 2026Article
- Deep learning-driven MRI segmentation of choroid plexus volume: a novel biomarker for cognitive impairment in type 2 diabetes mellitus.Japanese journal of radiology · 2026Article
- Glycated haemoglobin (HbA1c) levels and motor symptoms in Parkinson's disease.The Indian journal of medical research · 2026Observational
- Nrf2/NOX2 Pathway Dysregulation and Oxidative Stress Biomarkers in Gaucher Disease-Associated Parkinsonism: Insights Into a Potential Therapeutic Target.Journal of cellular and molecular medicine · 2026Article
- Hippocampal Lipocalin-2 in T2DM Associated Neurodegeneration: A Therapeutic Perspective.Neurochemical research · 2026Review
- Combined purslane ethanolic extract and metformin attenuate cognitive dysfunction in HFD/STZ-induced diabetic rats via modulation of oxidative stress, neuroinflammation, and neurotransmitters.BMC pharmacology & toxicology · 2026Article
- Clinical and Metabolic Predictors of Cognitive Impairment in Type 1 Diabetes: The Role of Peripheral Neuropathy and Hypoglycaemia Unawareness. Findings From a HAD-1 Study.Diabetes/metabolism research and reviews · 2026Article
- Methylglyoxal Affects Dopamine Homeostasis in SH-SY5Y Cells Through the Modulation of miR-190a and miR-214.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- A Longitudinal Investigation of Prediabetes, Diabetes, HbA1c and Cognitive Trajectories Among Cognitively Unimpaired Individuals.Journal of the American Geriatrics Society · 2026Article
- Association between cognitive function and all-cause mortality among US older adults with cardiovascular-kidney-metabolic syndrome.BMC geriatrics · 2026Article
- A review of risk factors and intervention measures for comorbidity of diabetes and mental disorders.Frontiers in psychiatry · 2026Review
- Imaging Diagnosis of Mild Cognitive Impairment: A Bibliometric Analysis (1999-2024).Brain and behavior · 2025Article
- Exploring the effect and mechanism of action of Jinlida granules (JLD) in the treatment of diabetes-associated cognitive impairment based on network pharmacology with experimental validation.Annals of medicine · 2025Article
- Longitudinal investigation of the HbA1c/HDL-c ratio as a potential biomarker of cognitive decline among Chinese older adults: evidence from CHARLS.BMC public health · 2025Article
- Understanding diabetic encephalopathy: a model-based approach to explore cognitive and motor impairments through glutamatergic dysregulation.Molecular biology reports · 2025Article
- Atorvastatin improves long-term memory by reducing amyloid-β formation and neuronal damage in STZ-induced diabetic rats.Journal of molecular histology · 2025Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
Diabetes mellitus (DM) is a chronic metabolic disorder characterized by hyperglycemia, responsible for the onset of several long-term complications. Recent evidence suggests that cognitive dysfunction represents an emerging complication of DM, but the underlying molecular mechanisms are still obscure. Dopamine (DA), a neurotransmitter essentially known for its relevance in the regulation of behavior and movement, modulates cognitive function, too. Interestingly, alterations of the dopaminergic system have been observed in DM. This review aims to offer a comprehensive overview of the most relevant experimental results assessing DA's role in cognitive function, highlighting the presence of dopaminergic dysfunction in DM and supporting a role for glucotoxicity in DM-associated dopaminergic dysfunction and cognitive impairment. Several studies confirm a role for DA in cognition both in animal models and in humans. Similarly, significant alterations of the dopaminergic system have been observed in animal models of experimental diabetes and in diabetic patients, too. Evidence is accumulating that advanced glycation end products (AGEs) and their precursor methylglyoxal (MGO) are associated with cognitive impairment and alterations of the dopaminergic system. Further research is needed to clarify the molecular mechanisms linking DM-associated dopaminergic dysfunction and cognitive impairment and to assess the deleterious impact of glucotoxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.